Yuyan Tang

Dr. Yuyan Tang


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2024 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
YZYifan Zhu
Yifan Zhu
HHHaidong He
Haidong He
WSWeiqian Sun
Weiqian Sun
JWJiajun Wu
Jiajun Wu
YXYong Xiao
Yong Xiao
YTYuyan Tang
Yuyan Tang
IgA nephropathy (IgAN) is a major cause of primary glomerulonephritis characterized by mesangial deposits of galactose-deficient IgA1 (Gd-IgA1). Toll-like receptors (TLRs), particularly TLR4 are involved in the pathogenesis of IgAN. The role of gut microbiota on IgAN patients was recently investigated. However, whether gut microbial modifications of Gd-IgA1 through TLR4 play a role in IgAN remains unclear. We recruited subjects into four groups, including 48 patients with untreated IgAN, 22 treated IgAN patients (IgANIT), 22 primary membranous nephropathy (MN), and 31 healthy controls (HCs). Fecal samples were collected to analyze changes in gut microbiome. Gd-IgA1 levels, expression of TLR4, B-cell stimulators, and intestinal barrier function were evaluated in all subjects. C57BL/6 mice were treated with a broad-spectrum antibiotic cocktail to deplete the gut microbiota and then gavaged with fecal microbiota transplanted fromclinical subjects of every group. Gd-IgA1 and TLR4 pathway were detected in peripheral blood mononuclear cells (PBMCs) from IgAN and HCs co-incubated with Lipopolysaccharide (LPS) and TLR4 inhibitor. Compared with other three groups, different compositions and decreased diversity demonstrated gut dysbiosis in un-treated IgAN, especially the enrichment of Escherichia -Shigella. Elevated Gd-IgA1 levels were found in un-treated IgAN patients and correlated with gut dysbiosis, TLR4, B-cell stimulators, indexes of intestinal barrier damage, and proinflammatory cytokines. In vivo, mice colonized with gut microbiota from IgAN and IgANIT patients, copied the IgAN phenotype with the activation of TLR4/MyD88/NF-κB pathway, B-cell stimulators in the intestine, and complied with enhanced proinflammatory cytokines. In vitro, LPS activated TLR4/MyD88/NF-κB pathway, B-cell stimulators and proinflammatory cytokines in the PBMCs from IgAN patients, which resulted in overproduction of Gd-IgA1 and inhibited by TLR4 inhibitor. Our results illustrated that gut-kidney axis was involved in the pathogenesis of IgAN. Gut dysbiosis could stimulate the overproduction of Gd-IgA1 by TLR4 signaling pathway production and B-cell stimulators.

6 March 2023 in Kidney and Blood Pressure Research
Verified
Journal Article
Open access
PDF file
YTYuyan Tang
Yuyan Tang
YXYong Xiao
Yong Xiao
HHHaidong He
Haidong He
YZYifan Zhu
Yifan Zhu
WSWeiqian Sun
Weiqian Sun
MWMinggang Wei
Minggang Wei
Introduction: Numerous research works have shown that serum Gal-deficient (Gd) IgA1 levels are increased in IgA nephropathy (IgAN) patients and these levels are a dangerous risk factor for IgAN. A relationship between the gut microbiota and IgAN has been reported. Whether the gut microbiota participates in the pathogenesis of IgAN was still controversial. Methods: We evaluated changes in the gut flora and the levels of Gd-IgA1 in IgAN patients and healthy controls (HCs). We investigated the Gd-IgA1 levels in both blood and urine specimens. C57BL/6 mice were given a broad-spectrum antibiotic cocktail to deplete the endogenous gut flora. We established a model of IgAN in pseudosterile mice and investigated the expression of the markers of intestinal permeability, inflammation, and local immune responses. Results: Studies have shown that the levels of certain gut flora differ between IgAN patients and HCs. Moreover, elevated Gd-IgA1 levels were found in both the serum and urine. Interestingly, Coprococcus, Dorea, Bifidobacterium, Blautia, and Lactococcus, selected from 10 candidate biomarkers to predict risk in IgAN patients according to random forest analysis, were inversely associated with urinary Gd-IgA1 levels. Notably, the urine level of Gd-IgA1 could best distinguish IgAN patients from HCs. Additionally, the degree of kidney damage in pseudosterile mice with IgAN was more severe than that in mice with IgAN. Furthermore, the markers of intestinal permeability were significantly elevated in pseudosterile IgAN mice. Moreover, the inflammation responses (TLR4, MyD88, and NF-κB in intestinal and renal tissues; TNF-α and IL-6 in serum) and local immune responses (BAFF and APRIL in intestinal tissue) were upregulated in pseudosterile IgAN mice. Conclusions: The urine Gd-IgA1 level may be as a biomarker for the early screening of potential IgAN, and gut microbiota dysbiosis was demonstrated in IgAN, which might involve the dysfunction of the mucosal barrier, inflammation, and local immune responses.

22 April 2020 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
YTYuyan Tang
Yuyan Tang
HHHaidong He
Haidong He
PHPin Hu
Pin Hu
XXXudong Xu
Xudong Xu
Immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis worldwide, is the main cause of end‑stage renal disease. IgAN is characterized by the accumulation of immune complexes in the circulation, which contain abnormal levels of IgA. IgAN primarily results from galactose‑deficient IgA1 (Gd‑IgA1) and Gd‑IgA1 deposition in the renal mesangium, causing local proliferation and matrix expansion. Gd‑IgA1 has been confirmed as one of the key effectors in the pathogenesis of IgAN, but the origin of Gd‑IgA1 is not clear. Recent studies have shown that Gd‑IgA1 deposition could be the result of mucosally primed plasma cells and is associated with T cell dysregulation. T cells contribute to the IgA response and play an important role in the development of IgAN. In the present review, the latest discoveries regarding the role of T lymphocytes in the pathogenesis of IgAN have been summarized. Understanding these advances will allow novel therapeutic strategies for the treatment of IgAN.

18 October 2025 in Current Research in Microbial Sciences
Verified
Journal Article
Open access
YTYuyan Tang
Yuyan Tang
DZDong-Liang Zhang
Dong-Liang Zhang
LHLu-Sheng Huang
Lu-Sheng Huang
PHPing Hu
Ping Hu
PLPing Liu
Ping Liu
HHHaidong He
Haidong He
IgA nephropathy (IgAN), the most prevalent primary glomerulonephritis subtype, affects many patients worldwide. To identify new therapeutic targets for IgAN, this study aimed to investigate the role and mechanisms of gut microbiota metabolites in mesangial cell proliferation. Building on our prior finding of elevated serum sphingosine-1-phosphate (S1P) in IgAN patients versus healthy controls,we established complementary in vivo and in vitro models.Using humanized-gut microbiota mice and IgA1-stimulated mesangial cells, we examined S1P effects via receptor modulation and Chemokine ligand 2(CCL2)-Mesenchymal to epithelial transition factor(MET)-Focal Adhesion Kinase(FAK) pathway analysis, validated in renal biopsies. Treatment of human mesangial cells with aggregated IgA1 (aIgA1) successfully induced an IgAN phenotype, characterized by increased proliferation, reduced apoptosis, and significant intracellular IgA accumulation. This model demonstrated upregulated CCL2 expression, along with increased proportions of cells in S and G2 phases. Western blot analysis further revealed significant upregulation of MET, phosphorylated MET (Tyr1234/1235 and Tyr1349), Proliferating Cell Nuclear Antigen(PCNA), cyclin D1, S1PR1, and S1PR3 protein expression. Targeted intervention using CCL2 siRNA, the CCL2 inhibitor NOX-E36, and the MET inhibitor LY2801653 decreased IgA deposition, p-Met protein expression, and cell proliferation. Furthermore, S1P intervention in IgAN mesangial cell models significantly increased S1PR1, S1PR3, CCL2, and MET protein expression, promoting mesangial cell proliferation. Importantly, the CCL2-MET-FAK signaling pathway was activated in both the mice with an IgAN-like phenotype and IgAN patients. Disruption of the gut microbiota in IgAN increases CCL2 expression in renal mesangial cells, driven by the metabolite S1P. This, activates the MET/FAK signaling pathway, promoting mesangial cell proliferation and contributing to IgAN progression.Our findings support targeting S1P as a therapeutic strategy for IgAN.

21 August 2018 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
YTYuyan Tang
Yuyan Tang
HHHaidong He
Haidong He
WSWeiqian Sun
Weiqian Sun
PHPin Hu
Pin Hu
XCXia Chen
Xia Chen
XXXudong Xu
Xudong Xu
Currently, there is no clear evidence that advocates the widespread use of corticosteroids for the treatment of immunoglobulin A nephropathy (IgAN) with minimal proteinuria (<1 g/day). The recent Kidney Disease: Improving Global Outcomes Clinical Practice Guideline recommends supportive corticosteroid treatment. In the present study, 45 IgAN patients with high renal pathological scores and minimal proteinuria were enrolled. The patients were randomly divided into two groups. The treatment group received methylprednisolone tablets in addition to angiotensin‑converting‑enzyme inhibitor (ACE‑I) and/or angiotensin‑receptor blocker (ARB) treatment. The control group only received ACE‑I and/or ARB treatment. In the treatment group, a single dose of 1 mg/kg (maximum 60 mg/day) methylprednisolone tablets was given daily followed by gradually decreasing dosage. The follow‑up time of the patients was 3 years. In addition, the underlying mechanisms were investigated. The results indicated that there was a significant reduction in the amount of urinary proteins in the treatment group compared with the control group. At the end of the follow‑up, the endpoint event rate of moderate or severe proteinuria and decrease in estimated glomerular filtration rate (eGFR) in the treatment group was significantly lower than the control group. Furthermore, higher levels of serum cytokines, interleukin (IL)‑4, IL‑17, transforming growth factor‑β1 and IL‑21, were detected in patients with IgAN compared with a group of healthy controls. There was no significant difference in IFN‑γ expression between the IgAN and healthy control groups. Furthermore, the expression of Janus kinase (Jak)1, Jak3, signal transducer and activator of transcription (STAT)3 and STAT6 was significantly upregulated in patients with IgAN compared with healthy controls. However, the expression levels of STAT5 and chaperone protein, C1GALT1 specific chaperone 1, in IgAN patients were significantly reduced compared with healthy controls. In addition, there was no significant difference in the expression of Jak2, tyrosine kinase 2, STAT1 and STAT4 between the two groups. In conclusion, for IgAN patients with minimal proteinuria and high renal pathological score corticosteroid therapy is likely to be effective. The dysregulation of serum cytokine levels in these patients with IgAN may have a role in the pathogenesis and progression of disease, which is associated with the activation of the JAK/STAT signaling pathway.

12 February 2014 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
YTYuyan Tang
Yuyan Tang
XCXiaohua Chen
Xiaohua Chen
YZYi Zhang
Yi Zhang
ZTZhenghao Tang
Zhenghao Tang
MZMeng Zhuo
Meng Zhuo
YYYongsheng Yu
Yongsheng Yu
Persistent hepatitis B virus (HBV) infection is characterized by a weak adaptive immune response, which is considered to be due to an imbalance of T helper cell types 1 and 2 (Th1/Th2). Suppressors of cytokine signaling (SOCS) family members, particularly SOCS1 and SOCS3, have been demonstrated to be important in the regulation of T cell differentiation. Previous studies by our group showed that the expressed and purified fusion protein of cytoplasmic transduction peptide (CTP) and HBV core antigen 18‑27 (HBcAg18‑27)‑tapasin was able to enter the cytoplasm of bone marrow‑derived dendritic cells (BMDCs), promoting the maturation of BMDCs and efficiently enhancing T cell immune responses in vitro. In the present study, HBcAg‑specific immune responses induced by CTP‑HBcAg18‑27‑tapasin in HBV were assessed in transgenic mice, and SOCS1 and SOCS3 were identified as negative regulators of this response. The Th1/Th2 cytokine ratio was analyzed by ELISA. The expression of T cell‑specific T‑box transcription factor (T‑bet) and GATA‑binding protein 3 (GATA‑3), SOCS1 and SOCS3 were detected by real‑time quantitative polymerase chain reaction and western blot analysis. The results demonstrated that CTP‑HBcAg18‑27‑tapasin significantly increased the Th1/Th2 cytokine ratio in HBV transgenic mice. CTP‑HBcAg18‑27‑tapasin immunization more efficiently suppressed the expression of serum hepatitis B surface antigen (HBsAg), HBV DNA as well as liver HBsAg and HBcAg in HBV transgenic mice. Furthermore, CTP‑HBcAg18‑27‑tapasin promotes T‑bet but reduces GATA‑3 expression. In addition, the expression of SOCS1 and SOCS3 was significantly downregulated in the CTP‑HBcAg18‑27‑tapasin group compared with the control groups. In conclusion, the present study demonstrated that CTP‑HBcAg18‑27‑tapasin enhanced the Th1/Th2 cytokine ratio and antiviral immunity by suppressing SOCS1/3 in HBV transgenic mice.